Downregulation of G2/mitotic-specific cyclinB1 triggers autophagy via AMPK-ULK1-dependent signal pathway in nasopharyngeal carcinoma cells.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
30 01 2019
Historique:
received: 22 11 2018
accepted: 14 01 2019
entrez: 1 2 2019
pubmed: 1 2 2019
medline: 5 6 2020
Statut: epublish

Résumé

CyclinB1 is a regulatory protein involved in mitosis. Multiple lines of evidence indicate that cyclinB1 depletion constrains proliferation and induces apoptosis in human tumor cells. The cells become susceptible to suffer a critical situation when cyclinB1 is downregulated. Autophagy is a major intracellular degradation system that recycles nutrients, removes damaged organelles, and promotes cell survival under stressful conditions, whereas the role of autophagy in cyclinB1-deprived neoplastic cell as well as the underlying molecular mechanism remains obscure. Here we pioneeringly elaborated that specific knockdown of cyclinB1 triggered autophagy via AMPK-ULK1-dependent signal pathway through the elevation of ROS, rather than ATP in the cell lines of CNE-1 and CNE-2. Moreover, ROS scavengers demonstrated that the observed effect of cyclinB1 silencing on AMPK phosphorylation was ROS dependent. Additionally, double knockdown of AMPK and cyclinB1 evidently abrogated cyclinB1 silencing-induced autophagy. Summarily, this study first revealed that downregulation of cyclinB1 induced autophagy via AMPK-ULK1-dependent signal pathway, which represents a key step toward unveiling the mechanism how cell cycle checkpoint proteins regulate autophagy.

Identifiants

pubmed: 30700698
doi: 10.1038/s41419-019-1369-8
pii: 10.1038/s41419-019-1369-8
pmc: PMC6353984
doi:

Substances chimiques

AMP-Activated Protein Kinases EC 2.7.11.31

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

94

Références

Cancer Res. 1996 Sep 15;56(18):4159-63
pubmed: 8797586
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Cell. 2007 Dec 14;131(6):1137-48
pubmed: 18083103
Int J Cancer. 2005 Sep 10;116(4):520-5
pubmed: 15818617
Cell. 2011 Nov 11;147(4):728-41
pubmed: 22078875
Cell Rep. 2017 Oct 3;21(1):1-9
pubmed: 28978464
Nat Commun. 2017 Jun 27;8:15916
pubmed: 28653662
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Ann N Y Acad Sci. 2006 Dec;1091:102-9
pubmed: 17341607
Nat Cell Biol. 2011 Feb;13(2):132-41
pubmed: 21258367
Oncogene. 2004 Jul 29;23(34):5843-52
pubmed: 15208674
Nat Rev Mol Cell Biol. 2009 Jul;10(7):458-67
pubmed: 19491929
Science. 2011 Jan 28;331(6016):456-61
pubmed: 21205641
Aging (Albany NY). 2013 Jul;5(7):515-30
pubmed: 24018842
Am J Clin Nutr. 2011 Apr;93(4):891S-6
pubmed: 21325438
J Cell Sci. 2004 Nov 1;117(Pt 23):5479-87
pubmed: 15509864
Cell. 2013 Jan 17;152(1-2):290-303
pubmed: 23332761
Free Radic Biol Med. 2009 May 15;46(10):1386-91
pubmed: 19268526
J Oral Pathol Med. 1999 Feb;28(2):77-81
pubmed: 9950254
J Cancer Res Clin Oncol. 1997;123(2):124-7
pubmed: 9030252
Clin Cancer Res. 2015 Nov 15;21(22):5037-46
pubmed: 26567363
Am J Pathol. 1997 Jan;150(1):15-23
pubmed: 9006317

Auteurs

Xianhe Xie (X)

Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China. xiexianhe@yahoo.com.

Wanzun Lin (W)

Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Weili Zheng (W)

Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Ting Chen (T)

Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Haitao Yang (H)

Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Lijun Sun (L)

Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Fei Huang (F)

Department of Central Laboratory, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Zili Wang (Z)

Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Heng Lin (H)

Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Long Chen (L)

Department of Intensive Care Unit, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Jun Liu (J)

Department of Central Laboratory, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Liyan Yang (L)

Department of Nephrology, The First Affiliated Hospital of Fujian Medical University, 20th Chazhong Road, 350005, Fuzhou, Fujian, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH